At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 175 enrolled
Drug / intervention
Normal Saline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized Placebo-Controlled Double-Blind Study of the Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction
In Brief
A Phase 3 clinical trial evaluating Normal Saline and Artefill for Atrophic Acne Scar. Completed, enrolled 175 participants across 10 sites.
Detailed Summary
The purpose of this study is to determine whether Artefill is safe and effective for the correction of atrophic facial acne scars.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrophic Acne Scar
CountriesUnited States
Collaboratorsethica Clinical Research Inc.
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
First PostedMar 2012
Primary CompletionApr 2013
Study CompletionFeb 2014
TodayJul 2026
First PostedMar 21, 2012
Enrollment StartFeb 1, 2012
Primary CompletionApr 1, 2013
Study CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 14.3 years ago
Interventions
Normal Salinedrug
Administration of up to 2 study treatments administered 6 weeks apart
Artefilldevice
Administration of up to 2 study treatments administered 6 weeks apart